RNfinity
Research Infinity Logo, Orange eye of horus, white eye of Ra
  • Home
  • Submit
    Research Articles
    Ebooks
  • Articles
    Academic
    Ebooks
  • Info
    Home
    Subject
    Submit
    About
    News
    Submission Guide
    Contact Us
    Personality Tests
  • Login/sign up
    Login
    Register

Oncology

Register to submit your paper, and Start Earning from your Research Articles

Share Your Oncology Research — Publish and Earn

In the rapidly evolving world of cancer research and oncology, timely knowledge sharing can make a real difference in patient outcomes and therapeutic development. Whether you're studying tumor biology, clinical oncology, or cutting-edge immunotherapy techniques, our multidisciplinary publishing platform provides an open space for your discoveries — with monetization opportunities built-in.

Why Publish Oncology Articles with Us?

Traditional peer review can delay the visibility of important oncology findings. Our non-peer-reviewed model allows you to share impactful cancer research directly and rapidly with fellow researchers, medical professionals, and healthcare innovators worldwide. From lab studies to clinical observations, your work can reach the audience it deserves.

From Benchside Discovery to Bedside Impact

Cancer research drives breakthroughs in early detection, treatment protocols, and patient care. Whether your focus is on genomics, targeted therapies, or epidemiological cancer trends, our platform invites contributions from all corners of the oncology community. Your work can inform real-world decisions and fuel future research directions.

Monetize Your Expertise

Publishing isn't only about academic recognition; it's also about earning value for your efforts. Our platform gives oncology researchers the option to monetize their content while contributing to the global cancer research conversation. If you're seeking an alternative to conventional medical journals, this is your invitation to submit.

Join a growing network of oncologists, cancer research specialists, and medical writers. Submit your oncology articles today and turn your insights into both impact and income.

Biomedical

Assessment of reproducibility of cancer survival risk predictions across medical centers

Hung-Chia Chen,

Hung-Chia Chen

James J Chen

James J Chen


Background

Two key considerations in evaluating survival prediction models are predictability (the ability to accurately predict survival risks) and reproducibility (the ability to generalize predictions across studies or centers). This study explores approaches to assessing the reproducibility of survival risk predictions across medical...
6 months ago

Biomedical

Progesterone Exposure and Breast Cancer Risk—Addressing Barriers

Seema A. Khan

Seema A. Khan

Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicaqgo, Illinois


This article addresses the role of progesterone exposure in breast cancer risk, focusing on both biological and technical barriers in studying progesterone’s impact. Research indicates that higher progesterone levels in postmenopausal women may modestly increase breast cancer risk, with a stronger association for invasive breast cancers. The study also highlights the complex relationship between...
7 months ago

Biomedical

Single Hormone Receptor–Positive Breast Cancer—Signal or Noise?

Vasily Giannakeas

Vasily Giannakeas

Women’s College Research Institute, Toronto, Ontario, Canada


Canonical predictors for the prognosis of breast cancer include estrogen receptor (ER), progesterone receptor (PR), and ERBB2 (formerly HER2) receptor. In most cases, positive ER status is auspicious, but there are exceptions (young women, black women, and BRCA2 mutation carriers). The simplest designation, hormone receptor–positive cancers, includes tumors that express ER and/or PR (hormone rec...
7 months ago

Biomedical

Predictability: A new distinguishing feature of cancer?

Ofer N. Gofrit,

Ofer N. Gofrit

Ariel Aviv

Ariel Aviv


Cancer is a consequence of stochastic (mutations, genetic, and epigenetic instabilities) and deterministic (evolutionary bottlenecks) events. Stochastic events are less amenable to prediction, whereas deterministic events yield more predictable results. The relative contribution of these opposing forces determines cancer predictability, which affects the accuracy of our prognostic predictions and ...
7 months ago

Biomedical

Evaluation and comparison of hereditary Cancer guidelines in the population

Jordon B. Ritchie,

Jordon B. Ritchie

NULL

Cecelia Bellcross,

Cecelia Bellcross

NULL

Caitlin G. Allen,

Caitlin G. Allen

NULL

Lewis Frey,

Lewis Frey

NULL

Heath Morrison,

Heath Morrison

NULL

Joshua D. Schiffman,

Joshua D. Schiffman

NULL

Brandon M. Welch

Brandon M. Welch

NULL


Background Family health history (FHx) is an effective tool for identifying patients at risk of hereditary cancer. Hereditary cancer clinical practice guidelines (CPG) contain criteria used to evaluate FHx and to make recommendations for genetic consultation. Comparing different CPGs used to evaluate a common set of FHx provides insight into how well the CPGs perform, the extent of agreement acro...
8 months ago

Biomedical

A sheep in wolf's clothing; a case of renal leiomyoma masquerading as hereditary leiomyomatosis and renal cell carcinoma

Nicole Uzzo,

Nicole Uzzo

NULL

Matthew Loecher,

Matthew Loecher

NULL

Robert G. Uzzo,

Robert G. Uzzo

NULL

Daniel D. Eun

Daniel D. Eun

NULL


Introduction: Active surveillance has become a standard of care for the management of small renal masses. Decision to transition from surveillance to intervention relies on several factors including growth kinetics, histologic grade on biopsy and patient comorbidities. Management of renal masses in pregnancy presents a unique change when clinical triggers must be weighed with risk to fetus. We pre...
8 months ago

Biomedical

Hereditary Cancer Syndromes: Identifying and Managing High-Risk Patients

zulqarnain bhalwal

zulqarnain bhalwal

NULL


Summary

Hereditary cancer syndromes are inherited conditions that increase the risk of cancer, affecting 5-10% of cases. Key factors for identifying high-risk patients include personal/family cancer history and genetic mutations. Management strategies involve surveillance (screening), risk reduction (lifestyle changes, surgery), and chemoprevent...
8 months ago

Biomedical

Current status of inherited pancreatic cancer

Marek Olakowski,

Marek Olakowski

NULL

Łukasz Bułdak

Łukasz Bułdak

NULL


Background It is estimated that about 10% of pancreatic cancer cases have a genetic background. People with a familial predisposition to pancreatic cancer can be divided into 2 groups. The first is termed hereditary pancreatic cancer, which occurs in individuals with a known hereditary cancer syndrome caused by germline single gene mutations (e.g.,BRCA1/2,CDKN2A). The second is considered as fami...
8 months ago

Biomedical

Advanced adenomas may be a red flag for hereditary cancer syndromes

Swati G. Patel,

Swati G. Patel

NULL

Heather Hampel,

Heather Hampel

NULL

Derek Smith,

Derek Smith

NULL

Dexiang Gao,

Dexiang Gao

NULL

Myles Cockburn,

Myles Cockburn

NULL

Fay Kastrinos

Fay Kastrinos

NULL


Background: 16–25% of colorectal cancers (CRCs) diagnosed under age 50 are associated with hereditary cancer syndromes. Advanced adenomas are considered precursors to CRC. Although polyp removal prevents cancer, polypectomy does not change underlying genetic risk. Patients with isolated advanced polyps do not currently qualify for genetic testing unless they have a personal or family history of ...
8 months ago

Biomedical

Hereditary leiomyomatosis and renal cell cancer syndrome

A. K. Prabodhana Ranaweera,

A. K. Prabodhana Ranaweera

NULL

D. Hettiarachchi,

D. Hettiarachchi

NULL

K. W. Gunawardena,

K. W. Gunawardena

NULL

M. D. S. Lokuhetty,

M. D. S. Lokuhetty

NULL

V. H. W. Dissanayake

V. H. W. Dissanayake

NULL


Introduction: Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is a rare autosomal dominantly inherited cancer predisposing syndrome giving rise to cutaneous and uterine leiomyomatosis, leiomyosarcoma and renal cell cancer. Patients with this syndrome harbours germline pathogenic variants in the fumarate hydratase (FH) gene. Case presentation: A 28-year-old Sri Lankan female, a pro...
8 months ago

Related Subjects

Anatomy Biochemistry Epidemiology Genetics Neuroscience Psychology Medicine Musculoskeletal science Pediatrics Pathology Pharmacology Physiology Psychiatry Primary care Women and reproductive health

Showing Page 1 to 2

  • ‹
  • 1
  • 2
  • ›

Follow Us

  • Xicon
  • Contact Us
  • Privacy Policy
  • Terms and Conditions

5 Braemore Court, London EN4 0AE, Telephone +442082758777

© Copyright 2025 All Rights Reserved.